Company news

Ascendis Pharma A/S news in 2026

Ascendis Pharma A/S's news releases, calls and decks from 2026, newest first.

View company

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

October 26, 2026

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

October 16, 2026

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

October 6, 2026

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

September 14, 2026

Ascendis Announces Planned $400 Million Share Repurchase Program

September 14, 2026

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

September 9, 2026

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 8, 2026

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

September 7, 2026

Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

August 31, 2026

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

August 25, 2026

Ascendis Pharma Reports Second Quarter 2026 Financial Results

August 13, 2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

August 6, 2026

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

June 30, 2026

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

June 26, 2026

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

June 25, 2026

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

June 13, 2026

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

June 8, 2026

Ascendis Pharma Reports First Quarter 2026 Financial Results

May 7, 2026

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

May 6, 2026

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

April 30, 2026

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

April 21, 2026

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

April 20, 2026

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

April 8, 2026

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

April 6, 2026

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

March 17, 2026

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

March 16, 2026

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

March 2, 2026

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

February 27, 2026

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults

February 6, 2026

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

February 4, 2026

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

January 9, 2026

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

January 8, 2026

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Calls in 2026

Decks in 2026